{"id":28253,"date":"2024-06-10T12:37:00","date_gmt":"2024-06-10T07:07:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=28253"},"modified":"2025-10-09T17:18:45","modified_gmt":"2025-10-09T11:48:45","slug":"myelofibrosis-treatment-landscape","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape","title":{"rendered":"The Dynamic Landscape of Myelofibrosis Treatment: A 2024 Perspective"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d00622a3c47\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d00622a3c47\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\/#JAKAFIs_dominance_in_the_myelofibrosis_treatment\" >JAKAFI\u2019s dominance in the myelofibrosis treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\/#With_a_broader-than-expected_label_OJJAARAS_poses_a_threat_to_JAKAFI\" >With a broader-than-expected label, OJJAARA\u2019S poses a threat to JAKAFI<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\/#Current_unmet_needs_in_myelofibrosis_treatment_despite_approved_therapies\" >Current unmet needs in myelofibrosis treatment despite approved therapies<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\/#Promising_emerging_therapies_for_myelofibrosis_treatment_beyond_JAK_inhibitors\" >Promising emerging therapies for myelofibrosis treatment beyond JAK inhibitors<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\/#Conclusion\" >Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, <strong>Janus kinase (JAK) inhibitors<\/strong> have become the mainstay of pharmacologic therapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-epidemiology-forecast\">myelofibrosis patients<\/a>. As seen by two recent large acquisitions for billions of dollars with late-stage myelofibrosis companies, myelofibrosis is a financially lucrative market. This implies that promising results from newly developed medicines might potentially pave the way for licensing prospects as well.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-jakafi-s-dominance-in-the-myelofibrosis-treatment\"><span class=\"ez-toc-section\" id=\"JAKAFIs_dominance_in_the_myelofibrosis_treatment\"><\/span><strong>JAKAFI\u2019s dominance in the myelofibrosis treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The oral JAK1\/JAK2 inhibitor <strong>JAKAFI <\/strong>(ruxolitinib) was initially approved by the FDA in <strong>2011<\/strong> for myelofibrosis, based on <strong>Phase III COMFORT<\/strong> trials. <strong>Over a decade later, JAKAFI continues to be the standard of care in higher-risk myelofibrosis<\/strong>.&nbsp;<\/p>\n\n\n\n<p>The <strong>second JAK inhibitor<\/strong> approved for the treatment of myelofibrosis was <strong>INREBIC <\/strong>(fedratinib), approved in 2019. The <strong>JAKARTA<\/strong> study served as the basis for approval for INREBIC and was contemporary to the COMFORT studies that led to the approval of JAKAFI. Research indicates that INREBIC and JAKAFI have <strong>similar efficacy <\/strong>in myelofibrosis patients.<strong> However, their toxicity profiles differ, with INREBIC having a risk of encephalopathy, leading to a black box warning on the label<\/strong>.&nbsp;<\/p>\n\n\n\n<p>The <strong>third approved <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-mf-market\"><strong>JAK inhibitor<\/strong> for myelofibrosis<\/a> was <strong>VONJO <\/strong>(pacritinib). The approval was based largely on the <strong>PERSIST-2 <\/strong>trial, where patients who were previously treated with JAK inhibitors, who were <strong>thrombocytopenic (platelet counts less than 100,000<\/strong>), were randomized between VONJO<strong> <\/strong>and the best available therapy.&nbsp;<\/p>\n\n\n\n<p>The <strong>fourth and most recently approved JAK<\/strong> <strong>inhibitor <\/strong>was <a href=\"https:\/\/www.delveinsight.com\/blog\/momelotinib-for-myelofibrosis-treatment\"><strong>OJJAARA <\/strong>(momelotinib)<\/a> by <strong>GSK<\/strong>. In September 2023, the US FDA approved OJJAARA<strong> <\/strong>for the treatment of intermediate or high-risk myelofibrosis, including primary or secondary myelofibrosis, in adults with anemia. It was supported by data from the pivotal <strong>MOMENTUM<\/strong> study and a subpopulation of adult patients with anemia from the <strong>SIMPLIFY-1 Phase III<\/strong> trial.<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-32bb8c64-7fff-1492-716f-3dbd5fc5ccc5\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"center\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"89\" \/><col width=\"146\" \/><col width=\"106\" \/><col width=\"75\" \/><col width=\"142\" \/><col width=\"91\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #bfe6ff; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\" colspan=\"6\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: center; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">FDA-approved Drugs for the Treatment of Myelofibrosis<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company Name<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Molecular targets<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">US Approval Date<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Target pool<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Cost of Therapy per month<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">(in the US)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">JAKAFI<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Incyte\/Novartis<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">JAK1 &amp; 2<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">November 2011<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Intermediate or high-risk, including primary<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">USD 14,187<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">INREBIC<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Bristol Myers Squibb (Celgene\/Impact Biomedicines)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">JAK2 &amp; FLT3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">August&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">2019<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Intermediate or high-risk, primary or secondary (boxed warning of encepalopathy)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">USD 21,000<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">VONJO<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Sobi (CTI Biopharma)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">JAK2 &amp; FLT3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">February 2022<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Intermediate or high-risk, primary or secondary (accelerated approval)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">USD 19,500<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">OJJAARA<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">GSK (Sierra)<\/span><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\"><span class=\"Apple-tab-span\" style=\"white-space: pre;\"> <\/span><\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">JAK1\/2 &amp; ACVR1<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">September 2023<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Intermediate or high-risk, primary or secondary, in anemia patients<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: middle; background-color: #f5f5f5; padding: 0pt 5.4pt 0pt 5.4pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; text-align: justify; margin-top: 10pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">USD 26,900<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>The approval of VONJO and INREBIC has not notably affected JAKAFI. However, the latest approval of a JAK inhibitor could potentially have some impact. Last year (in 2023) JAKAFI generated ~<strong>USD 1.08 billion<\/strong> in US net product revenues. It is worth mentioning that while JAKAFI has garnered approvals across various indications over the years, <strong>polycythemia vera and myelofibrosis stand out as the primary revenue-generating indications for this drug<\/strong>. No other approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-mf-market\">myelofibrosis treatment therapies<\/a> come close to matching the annual sales of JAKAFI. In 2023, VONJO&#8217;s revenue was around <strong>USD 67 million<\/strong>, whereas OJJAARA\u2019s revenue was approximately <strong>USD 41 million<\/strong>. INREBIC generated a total of <strong>USD 110 million<\/strong> in product revenues by the end of 2023.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"310\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-1024x310.jpg\" alt=\"Total Patient Share of JAKAFI by Indication (2023)\" class=\"wp-image-28259\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-1024x310.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-300x91.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-150x45.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-768x232.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-1536x465.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023-1568x474.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123348\/Total-Patient-Share-of-JAKAFI-by-Indication-2023.jpg 1964w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>JAKAFI stands as the undisputed champion in the realm of myelofibrosis therapeutics, reigning supreme amidst its recently approved competitors. While playing defense against new rivals in myelofibrosis, Incyte believes the rare blood disorder polycythemia vera will serve as JAKAFI\u2019s main growth driver in the future. Meanwhile, there is a concern regarding JAKAFI\u2019s upcoming loss of exclusivity in 2028. Novel combinations represent another strategy Incyte is banking on.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"With_a_broader-than-expected_label_OJJAARAS_poses_a_threat_to_JAKAFI\"><\/span><strong>With a broader-than-expected label, OJJAARA\u2019S poses a threat to JAKAFI<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The market leader, JAKAFI has been a dominant force for 12 years. However, the market authorization of OJJAARA presents potential competition. With just <strong>USD 3 million<\/strong> in upfront cash, up to <strong>USD 195 million<\/strong> in milestones, and tiered royalties, Sierra purchases momelotinib from Gilead after the failures of <strong>Simplify-1 and 2 trials<\/strong>. Following its success in the <strong>phase III Momentum trial<\/strong> for post-JAKAFI myelofibrosis, GSK pays <strong>USD 1.9 billion<\/strong> in cash to acquire <strong>Sierra<\/strong>. Unlike other approved myelofibrosis treatment therapies, OJJAARA\u2019s FDA label lacks highlighted toxicity warnings and has a broad label including primary and secondary myelofibrosis in adults with anemia. The FDA approved this <a href=\"https:\/\/www.delveinsight.com\/blog\/momelotinib-for-myelofibrosis-treatment\">therapy for patients with myelofibrosis<\/a> regardless of their treatment history. About half of the first-line myelofibrosis population is anemic at diagnosis. <strong>Given OJJAARA\u2019S label, anemic patients might go directly to the GSK drug as their initial myelofibrosis treatment option<\/strong>. OJJAARA also targets patients who are ineligible for JAKAFI treatment, as JAKAFI could potentially worsen anemia during myelofibrosis therapy. Data suggests that there is around a 50% risk that JAK inhibitors may worsen anemia. Approximately 70% to 80% of myelofibrosis patients are anemic by the end of frontline therapy with JAK inhibitors, and nearly half of those patients need transfusions. <strong>Sierra&#8217;s focus on addressing anemia has effectively differentiated OJJAARA from JAKAFI.<\/strong>&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"310\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-1024x310.jpg\" alt=\"DelveInsight's Market Size Estimates for Myelofibrosis by Currently Approved JAK Inhibitors in the US\" class=\"wp-image-28260\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-1024x310.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-300x91.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-150x45.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-768x232.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-1536x465.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US-1568x474.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123435\/DelveInsights-Market-Size-Estimates-for-Myelofibrosis-by-Currently-Approved-JAK-Inhibitors-in-the-US.jpg 1964w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Current_unmet_needs_in_myelofibrosis_treatment_despite_approved_therapies\"><\/span><strong>Current unmet needs in myelofibrosis treatment despite approved therapies<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>For some patients, dose-dependent anemia and thrombocytopenia related to ruxolitinib may lead to discontinuation of treatment. While dosing adjustments can alleviate anemia and thrombocytopenia, this may compromise clinical outcomes.&nbsp;<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>After 2\u20133 years of myelofibrosis treatment, some patients who initially responded to ruxolitinib develop drug resistance<\/strong>, likely due to its limited impact on driver mutations burden.&nbsp;<\/li>\n\n\n\n<li>JAK inhibitors have minimal effects on achieving complete hematological remission and normalizing blood counts without strong evidence of disease-modifying effects. <strong>These obstacles underscore the necessity for alternative therapies for myelofibrosis beyond JAK inhibitors.<\/strong>&nbsp;<\/li>\n\n\n\n<li>Allogeneic-hematopoietic stem cell transplantation remains the only curative option for patients with myelofibrosis but is limited to a subset of high-risk and fit patients.&nbsp;<\/li>\n\n\n\n<li><strong>Currently approved therapies are associated with significant adverse effects.<\/strong> Before the approval, a clinical hold was also put on the development of pacritinib over concern of increased risk of bleeding and cardiac events. Major adverse cardiac events are a class effect. They have been observed in ruxolitinib, fedratinib, and other JAK inhibitors as well, and even in JAK inhibitors used to treat other indications. So, certainly, something to keep in mind when using JAK inhibitors in the clinic.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Promising_emerging_therapies_for_myelofibrosis_treatment_beyond_JAK_inhibitors\"><\/span><strong>Promising emerging therapies for myelofibrosis treatment beyond JAK inhibitors<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although existing JAK inhibitors prescribed for myelofibrosis treatment have demonstrated considerable clinical advantages by reducing symptoms and reducing spleen enlargement, they have not exhibited definitive disease-modifying effects, leading to most patients discontinuing the medication within one to two years. Owing to these reasons, the MPN community is keen on exploring <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-pipeline-insight\">potential alternative myelofibrosis treatments<\/a> beyond JAK inhibitors that could offer additional benefits.&nbsp;<\/p>\n\n\n\n<p>Different mechanisms other than JAK inhibitors under investigation are <strong>telomerase inhibitor <\/strong>(imetelstat), <strong>BCL-XL\/BCL-2 inhibitor <\/strong>(navitoclax), <strong>MDM2 protein inhibitor <\/strong>(navtemadlin), <strong>BET inhibitor <\/strong>(pelabresib), and others which may cover the patient need and provide an alternative myelofibrosis treatment for the patients. In addition to this, there is a growing focus on combining JAK inhibitors with other therapies to improve outcomes. <strong>Two Phase III trials showed adding drugs to ruxolitinib significantly increased spleen volume reduction compared to ruxolitinib alone.<\/strong> MANIFEST-2 added pelabresib, a BET inhibitor, while TRANSFORM-1 added navitoclax, a BCL2 inhibitor, leading to a doubling in patients achieving \u226535% spleen volume reduction at 24 weeks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>JAK inhibitors have significantly transformed myelofibrosis treatment since the approval of JAKAFI in 2011. Subsequent approvals of INREBIC, VONJO, and OJJAARA provided additional options, each with unique benefits and risks. OJJAARA, approved in 2023, offers a promising alternative, especially for anemic patients, and poses a potential challenge to JAKAFI&#8217;s dominance. However, the need for better myelofibrosis treatments remains. Current research explores novel therapies and combination treatments, which have shown the potential to improve outcomes. The <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-mf-market\">myelofibrosis treatment market<\/a> is attractive, driving substantial investments and acquisitions. The future of myelofibrosis treatment lies in these innovative approaches, aiming to overcome the limitations of existing JAK inhibitors and enhance patient quality of life.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-mf-market\"><img decoding=\"async\" width=\"1024\" height=\"256\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--1024x256.png\" alt=\"Myelofibrosis Market Outlook \" class=\"wp-image-28258\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook--1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123255\/Myelofibrosis-Market-Outlook-.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-faqs\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span>FAQs<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1760010480460\"><strong class=\"schema-faq-question\"><strong>How is myelofibrosis diagnosed?<\/strong><\/strong> <p class=\"schema-faq-answer\">Diagnosis typically involves blood tests, bone marrow biopsy, genetic testing (such as JAK2, CALR, or MPL mutations), and imaging studies to assess spleen and liver size.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760010488623\"><strong class=\"schema-faq-question\"><strong>What is the role of JAK inhibitors in myelofibrosis treatment?<\/strong><\/strong> <p class=\"schema-faq-answer\">JAK inhibitors have transformed the management of myelofibrosis by reducing spleen size and alleviating symptoms. However, they do not alter the disease course, and long-term use can lead to side effects, such as anemia.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760010501442\"><strong class=\"schema-faq-question\"><strong>How does OJJAARA differ from other myelofibrosis treatments?<\/strong><\/strong> <p class=\"schema-faq-answer\">OJJAARA (momelotinib), approved by the FDA in 2023, is an oral JAK inhibitor that offers a promising alternative, especially for anemic patients. It poses a potential challenge to JAKAFI\u2019s dominance in the treatment landscape.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1760010511335\"><strong class=\"schema-faq-question\"><strong>What are the other classes in development for myelofibrosis other than JAK inhibitors?<\/strong><\/strong> <p class=\"schema-faq-answer\">Different mechanisms, other than JAK inhibitors, are under investigation, including telomerase inhibitors (imetelstat), BCL-XL\/BCL-2 inhibitors (navitoclax), MDM2 protein inhibitors (navtemadlin), and BET inhibitors (pelabresib), among others, which may address the patient&#8217;s needs and provide an alternative myelofibrosis treatment.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis patients. As seen by two recent large acquisitions for billions of dollars with [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":28255,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16937,17376,5005,5008,5007,5009,5006,18063,21296],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-28253","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-jak-inhibitors","tag-jakafi","tag-myelofibrosis","tag-myelofibrosis-epidemiology","tag-myelofibrosis-market","tag-myelofibrosis-pipeline","tag-myelofibrosis-therapy-market","tag-myelofibrosis-treatment","tag-ojjaara","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Myelofibrosis Treatment in 2024: New Horizons and Innovations<\/title>\n<meta name=\"description\" content=\"The future of myelofibrosis treatment lies in the innovative approaches, aiming to overcome the limitations of existing JAK inhibitors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myelofibrosis Treatment in 2024: New Horizons and Innovations\" \/>\n<meta property=\"og:description\" content=\"The future of myelofibrosis treatment lies in the innovative approaches, aiming to overcome the limitations of existing JAK inhibitors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-10T07:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-09T11:48:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123148\/myelofibrosis-treatment-landscape.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Myelofibrosis Treatment in 2024: New Horizons and Innovations","description":"The future of myelofibrosis treatment lies in the innovative approaches, aiming to overcome the limitations of existing JAK inhibitors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape","og_locale":"en_US","og_type":"article","og_title":"Myelofibrosis Treatment in 2024: New Horizons and Innovations","og_description":"The future of myelofibrosis treatment lies in the innovative approaches, aiming to overcome the limitations of existing JAK inhibitors.","og_url":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-06-10T07:07:00+00:00","article_modified_time":"2025-10-09T11:48:45+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123148\/myelofibrosis-treatment-landscape.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape","url":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape","name":"Myelofibrosis Treatment in 2024: New Horizons and Innovations","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123148\/myelofibrosis-treatment-landscape.png","datePublished":"2024-06-10T07:07:00+00:00","dateModified":"2025-10-09T11:48:45+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The future of myelofibrosis treatment lies in the innovative approaches, aiming to overcome the limitations of existing JAK inhibitors.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010480460"},{"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010488623"},{"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010501442"},{"@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010511335"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123148\/myelofibrosis-treatment-landscape.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123148\/myelofibrosis-treatment-landscape.png","width":466,"height":284,"caption":"myelofibrosis-treatment-landscape"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010480460","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010480460","name":"How is myelofibrosis diagnosed?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Diagnosis typically involves blood tests, bone marrow biopsy, genetic testing (such as JAK2, CALR, or MPL mutations), and imaging studies to assess spleen and liver size.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010488623","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010488623","name":"What is the role of JAK inhibitors in myelofibrosis treatment?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"JAK inhibitors have transformed the management of myelofibrosis by reducing spleen size and alleviating symptoms. However, they do not alter the disease course, and long-term use can lead to side effects, such as anemia.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010501442","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010501442","name":"How does OJJAARA differ from other myelofibrosis treatments?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"OJJAARA (momelotinib), approved by the FDA in 2023, is an oral JAK inhibitor that offers a promising alternative, especially for anemic patients. It poses a potential challenge to JAKAFI\u2019s dominance in the treatment landscape.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010511335","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/myelofibrosis-treatment-landscape#faq-question-1760010511335","name":"What are the other classes in development for myelofibrosis other than JAK inhibitors?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Different mechanisms, other than JAK inhibitors, are under investigation, including telomerase inhibitors (imetelstat), BCL-XL\/BCL-2 inhibitors (navitoclax), MDM2 protein inhibitors (navtemadlin), and BET inhibitors (pelabresib), among others, which may address the patient's needs and provide an alternative myelofibrosis treatment.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/06\/10123148\/myelofibrosis-treatment-landscape-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">JAK inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Jakafi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Myelofibrosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Myelofibrosis epidemiology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Myelofibrosis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Myelofibrosis pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Myelofibrosis therapy market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Myelofibrosis Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Ojjaara<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">JAK inhibitors<\/span>","<span class=\"advgb-post-tax-term\">Jakafi<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis epidemiology<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis market<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis pipeline<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis therapy market<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis Treatment<\/span>","<span class=\"advgb-post-tax-term\">Ojjaara<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 6 months ago"},"absolute_dates":{"created":"Posted on Jun 10, 2024","modified":"Updated on Oct 9, 2025"},"absolute_dates_time":{"created":"Posted on Jun 10, 2024 12:37 pm","modified":"Updated on Oct 9, 2025 5:18 pm"},"featured_img_caption":"myelofibrosis-treatment-landscape","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=28253"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28253\/revisions"}],"predecessor-version":[{"id":33651,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/28253\/revisions\/33651"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/28255"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=28253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=28253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=28253"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=28253"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=28253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}